Literature DB >> 28636211

Resolution of donor non-alcoholic fatty liver disease following liver transplantation.

Andrew D Posner1, Samuel T Sultan2, Norann A Zaghloul1, William S Twaddell1, David A Bruno2, Steven I Hanish2, William R Hutson1, Laci Hebert2, Rolf N Barth2, John C LaMattina2.   

Abstract

INTRODUCTION: Transplant surgeons conventionally select against livers displaying high degrees (>30%) of macrosteatosis (MaS), out of concern for primary non-function or severe graft dysfunction. As such, there is relatively limited experience with such livers, and the natural history remains incompletely characterized. We present our experience of transplanted livers with high degrees of MaS and microsteatosis (MiS), with a focus on the histopathologic and clinical outcomes.
METHODS: Twenty-nine cases were identified with liver biopsies available from both the donor and the corresponding liver transplant recipient. Donor liver biopsies displayed either MaS or MiS ≥15%, while all recipients received postoperative liver biopsies for cause.
RESULTS: The mean donor MaS and MiS were 15.6% (range 0%-60%) and 41.3% (7.5%-97.5%), respectively. MaS decreased significantly from donor (M=15.6%) to recipient postoperative biopsies (M=0.86%), P<.001. Similarly, MiS decreased significantly from donor biopsies (M=41.3%) to recipient postoperative biopsies (M=1.8%), P<.001. At a median of 68 days postoperatively (range 4-384), full resolution of MaS and MiS was observed in 27 of 29 recipients.
CONCLUSIONS: High degrees of MaS and MiS in donor livers resolve in recipients following liver transplantation. Further insight into the mechanisms responsible for treating fatty liver diseases could translate into therapeutic targets.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  biopsy; donors and donation: extended criteria; liver allograft function/dysfunction

Mesh:

Year:  2017        PMID: 28636211      PMCID: PMC5856244          DOI: 10.1111/ctr.13032

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  30 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Excellent outcomes of liver transplantation using severely steatotic grafts from brain-dead donors.

Authors:  Tiffany C L Wong; James Y Y Fung; Kenneth S H Chok; Tan To Cheung; Albert C Y Chan; William W Sharr; Wing Chiu Dai; See Ching Chan; Chung Mau Lo
Journal:  Liver Transpl       Date:  2016-02       Impact factor: 5.799

3.  The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment.

Authors:  Austin L Spitzer; Oliver B Lao; André A S Dick; Ramasamy Bakthavatsalam; Jeffrey B Halldorson; Matthew M Yeh; Melissa P Upton; Jorge D Reyes; James D Perkins
Journal:  Liver Transpl       Date:  2010-07       Impact factor: 5.799

Review 4.  Liver transplantation using fatty livers: always feasible?

Authors:  Lucas McCormack; Philipp Dutkowski; Ashraf Mohammad El-Badry; Pierre-Alain Clavien
Journal:  J Hepatol       Date:  2010-11-13       Impact factor: 25.083

5.  Similar outcome after transplantation of moderate macrovesicular steatotic and nonsteatotic livers when the cold ischemia time is kept very short.

Authors:  Andrie C Westerkamp; Marieke T de Boer; Aad P van den Berg; Annette S H Gouw; Robert J Porte
Journal:  Transpl Int       Date:  2014-12-29       Impact factor: 3.782

6.  Effect of graft steatosis on liver function and organ survival after liver transplantation.

Authors:  Martin K Angele; Markus Rentsch; Wolfgang H Hartl; Benedikt Wittmann; Christian Graeb; Karl Walter Jauch; Florian Loehe
Journal:  Am J Surg       Date:  2008-02       Impact factor: 2.565

7.  Steatosis of the hepatic graft as a risk factor for post-transplant biliary complications.

Authors:  Umberto Baccarani; Miriam Isola; Gian L Adani; Claudio Avellini; Dario Lorenzin; Anna Rossetto; Giuseppe Currò; Chiara Comuzzi; Pierluigi Toniutto; Andrea Risaliti; Franca Soldano; Vittorio Bresadola; Dino De Anna; Fabrizio Bresadola
Journal:  Clin Transplant       Date:  2010 Sep-Oct       Impact factor: 2.863

8.  Extended criteria donors in liver transplantation: adapting donor quality and recipient.

Authors:  M Gastaca
Journal:  Transplant Proc       Date:  2009-04       Impact factor: 1.066

Review 9.  Nonalcoholic fatty liver disease and liver transplantation.

Authors:  Paul Angulo
Journal:  Liver Transpl       Date:  2006-04       Impact factor: 5.799

10.  Reversal of graft steatosis after liver transplantation: prospective study.

Authors:  J Li; B Liu; L-N Yan; Y-X Zuo; B Li; Y Zeng; S F Zhang; F-G Li
Journal:  Transplant Proc       Date:  2009-11       Impact factor: 1.066

View more
  3 in total

1.  Moderately Macrosteatotic Livers Have Acceptable Long-Term Outcomes but Higher Risk of Immediate Mortality.

Authors:  Jurgis Alvikas; Andrew-Paul Deeb; Dana R Jorgensen; Marta I Minervini; Anthony J Demetris; Kristina Lemon; Xilin Chen; Hanna Labiner; Shahid Malik; Christopher Hughes; Abhinav Humar; Amit Tevar
Journal:  Transplant Proc       Date:  2021-04-27       Impact factor: 1.014

2.  A Novel Multidrug Combination Mitigates Rat Liver Steatosis Through Activating AMPK Pathway During Normothermic Machine Perfusion.

Authors:  Min Xu; Fangyu Zhou; Ola Ahmed; Gundumi A Upadhya; Jianluo Jia; Choonghee Lee; Jianwei Xing; Li Ye; So Hee Shim; Zhengyan Zhang; Kathleen Byrnes; Brian Wong; Jae-Sung Kim; Yiing Lin; William C Chapman
Journal:  Transplantation       Date:  2021-11-01       Impact factor: 5.385

Review 3.  Machine Perfusion for Extended Criteria Donor Livers: What Challenges Remain?

Authors:  Jeannette Widmer; Janina Eden; Mauricio Flores Carvalho; Philipp Dutkowski; Andrea Schlegel
Journal:  J Clin Med       Date:  2022-09-03       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.